Johnson & Johnson to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Johnson & Johnson (JNJ) PT Lowered to $141 at UBS Following 4Q Report
January 25, 2017 8:12 AM ESTUBS lowered its price target on Johnson & Johnson (NYSE: JNJ) to $141.00 (from $142.00) while maintaining a Buy rating following the company's 4Q earnings report.
Analyst Matt Miksic commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up... More
